BiomX, Inc.
🇺🇸United States
Clinical Trials
3
Active:1
Completed:1
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)A Study of Topical BX005-A in Subjects With Moderate to Severe Atopic Dermatitis
Phase 1
- Conditions
- Atopic Dermatitis
- First Posted Date
- 2022-02-15
- Last Posted Date
- 2022-02-15
- Lead Sponsor
- BiomX, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05240300
Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection
Phase 1
Active, not recruiting
- Conditions
- Chronic Pseudomonas Aeruginosa InfectionCystic Fibrosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- BiomX, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05010577
- Locations
- 🇺🇸
The University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
A Study to Evaluate the Safety, Tolerability, and Fecal Pharmacokinetics of BX002-A in Healthy Adults
Phase 1
Completed
- Conditions
- Healthy Volunteers
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2022-01-25
- Lead Sponsor
- BiomX, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04737876
- Locations
- 🇺🇸
Medical Facility, Cincinnati, Ohio, United States
News
No news found